Avellino Enters Into Distribution Agreement With Keeler to Sell Genetic Eye Test AvaGen

Avellino Lab USA and Keeler have entered into an agreement where Keeler will distribute AvaGen on its US website.

Terms of the deal were not disclosed. 

AvaGen is the first genetic test that helps determine a patient’s risk of keratoconus and the presence of TGFBI corneal dystrophies. The test allows for more confident management and treatment for patients with these conditions in order to protect and preserve patient vision. The test examines 75 keratoconus-related genes and more than 2,000 variants of those genes to develop an actionable genetic risk score for keratoconus.

“We are excited to partner with Keeler and provide expanded availability to this one-of-a-kind genetic test that can help earlier detect both keratoconus and certain corneal dystrophies,” Avellino Global Head of Sales and Marketing Joe Boyd said in a company news release. “With these type of genetic conditions, early detection is key in protecting vision, and this new distribution channel will provide eye care professionals another way to access this groundbreaking test.”

“Keeler’s vision is ‘a world without vision loss,’ and AvaGen is a wonderful addition to our suite of products that supports our business strategy and goal to provide quality products to licensed medical professionals,” says Keeler Vice President of Business and Channel Management Eugene VanArsdale. “This will be the first ophthalmic genetic-based test we offer on our US website, and we are thrilled to offer the eye care community a new way to obtain this important diagnostic offering.”

AvaGen is expected to be available on the Keeler US website https://www.keelerusa.com by late January.